P1.16B supplemental budget para sa nabakunahan ng Dengvaxia aprub na | Bandera

P1.16B supplemental budget para sa nabakunahan ng Dengvaxia aprub na

Leifbilly Begas |May 22,2018
facebook
share this

P1.16B supplemental budget para sa nabakunahan ng Dengvaxia aprub na

Leifbilly Begas - May 22, 2018 - 07:09 PM

INAPRUBAHAN na ng House committee on appropriations ang P1.161 bilyong supplemental budget para tulungan ang may 900,000 nabakunahan ng Dengvaxia.

Ayon sa chairman ng komite na si Davao City Rep. Karlo Nograles walang expiration ang pondo na magagamit lagpas ng 2019 hindi katulad ng kasalukuyang budget na dalawang taon lamang ang validity period.

“It will be effective until it is fully spent,” ani Nograles sa pagdinig kahapon. “The fund can be used and (its use will be) extended to 2022. It will be like perpetual fund.”

Hiniling ni Department of Health Usec. Rolando Domingo sa Kamara de Representantes at Department of Budget and Management na huwag lagyan ng prescription period ang supplemental budget.

Ang pondo ay manggagaling sa P1.16 bilyong ibinalik ng Sanofi Pasteur, ang manufacturer ng Dengvaxia.

Sa naturang pondo, P945.8 milyon ang inilaan para sa medical assistance sa mga nabakunahan.

Sinabi ni Nograles na nais nila na agad na maaprubahan ang panukala bago mag-adjourn ang sesyon sa Hunyo 1.

Ayon kay Domingo mayroong sertipikasyon mula sa Pangulo ang panukala.

“This committee will send it to the floor…Could you send me the certification because I plan to have this approved on the floor by next week, for second and third reading. We still have to send it to the Senate,” ani Nograles kay Domingo.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

Disclaimer: The comments uploaded on this site do not necessarily represent or reflect the views of management and owner of Bandera. We reserve the right to exclude comments that we deem to be inconsistent with our editorial standards.

What's trending